title: [Sarcoidosis following pegylated interferon therapy: two cases].
abstract: One side effect of the immunomodulatory effect of interferon is the possible triggering or exacerbation of systemic or cutaneous sarcoidosis. We report two new cases and offer an exhaustive review of the literature. A 39-year-old man with type C chronic active hepatitis developed new respiratory symptoms and pulmonary infiltrates with hilar and mediastinal adenopathy after 7 months of treatment with pegylated interferon. The evolution was favourable after stopping treatment. The second patient developed cutaneous lesions after 6 months of treatment. Resolution occurred after the discontinuation of the treatment. In these two cases ribavirin was stopped before the first signs of sarcoidosis.
authors.affiliation: Service d'Hépato-Gastroentérologie, Hôpital Saint Joseph, Marseille.
authors.forename: Souad
authors.initials: S
authors.lastname: Benali
authors.forename: Christian
authors.initials: C
authors.lastname: Boustière
authors.forename: Paul
authors.initials: P
authors.lastname: Castellani
authors.forename: Christine
authors.initials: C
authors.lastname: Cesari
authors.forename: Monique
authors.initials: M
authors.lastname: Jullien
authors.forename: Laurence
authors.initials: L
authors.lastname: Lecomte
authors.forename: Olivier
authors.initials: O
authors.lastname: Lebars
authors.forename: Gérard
authors.initials: G
authors.lastname: Lambot
authors.forename: Robert
authors.initials: R
authors.lastname: Loyer
authors.forename: Amina
authors.initials: A
authors.lastname: Masseboeuf
authors.forename: Hervé
authors.initials: H
authors.lastname: Perrier
authors.forename: Valérie
authors.initials: V
authors.lastname: Oules
authors.forename: Marc
authors.initials: M
authors.lastname: Bourlière
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins; D017565:Sarcoidosis, Pulmonary / Q000139:chemically induced*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a